Vaxcyte Inc Earnings

Vaxcyte Inc’s revenue jumped NaN% since last year same period to $0Mn in the Q1 2025. On a quarterly growth basis, Vaxcyte Inc has generated NaN% jump in its revenue since last 3-months.

Vaxcyte Inc’s net profit fell -48.09% since last year same period to $-140.72Mn in the Q1 2025. On a quarterly growth basis, Vaxcyte Inc has generated -2.65% fall in its net profits since last 3-months.

Vaxcyte Inc’s net profit margin jumped NaN% since last year same period to -Inf% in the Q1 2025. On a quarterly growth basis, Vaxcyte Inc has generated NaN% jump in its net profit margins since last 3-months.

Vaxcyte Inc’s earning per share (EPS) estimates for the current quarter stand at -0.98 - a 1.71% jump from last quarter’s estimates.

Vaxcyte Inc’s earning per share (EPS) estimates for the current year stand at -0.98.

Vaxcyte Inc’s earning per share (EPS) fell -22.35% since last year same period to -1.04 in the Q1 2025. This indicates that the Vaxcyte Inc has generated -22.35% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Vaxcyte Inc’s return on assets (ROA) stands at -0.15.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Vaxcyte Inc’s return on equity (ROE) stands at -0.2.